BY1921 / Chengdu Baiyu Pharma, Novartis - LARVOL DELTA

BY101921: Restoring interferon signaling and anti-tumor immunity through PARP7 inhibition. (ASCO 2024) - "BY101921, a potent and selective PARP7 inhibitor, demonstrates significant anti-tumor efficacy both as a monotherapy and in combo with anti-PD-1, while maintaining excellent tolerability in animal models. With favorable drug-like properties and a promising safety profile, BY101921 holds potential as an enhanced therapeutic option for cancer patients. At present, clinical studies investigating BY101921 as a single agent and in combo with anti-PD-1 are in the recruitment phase."

IO biomarker • Breast Cancer • Gastrointestinal Cancer • Hematological Disorders • Hepatology • Oncology • Ovarian Cancer • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • Squamous Cell Carcinoma • Targeted Protein Degradation • CXCL10 • IFNB1 • TIPARP

A Phase l Study of By101921, an Oral PARP7 Inhibitor, in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=60 | Recruiting | Sponsor: Chengdu Baiyu Pharmaceutical Co., Ltd.

Metastases • Monotherapy • New P1 trial • Oncology • Solid Tumor